Despite not being FDA-approved to treat or prevent COVID-19, drug demand continues to rise
The average number of monthly prescriptions for the antiparasitic drug ivermectin increased amid the COVID-19 pandemic, according to a claims analysis, which suggested a sharp increase in off-label use.
The drug is not authorized or approved by the FDA to prevent or treat COVID-19, although ivermectin abuse and overdoses have climbed amid the pandemic, as has ivermectin-related poisoning, according to Recent Health. Control centers are indicated by call. Consultant From the Centers for Disease Control and Prevention (CDC).
The latest analysis from Comodo Health analyzed state-level ivermectin prescriptions from January 2019 to May 2021 showed a 72% increase in the average number of monthly prescriptions from 39,864 to 68,428 as well as a 34% monthly increase over the pre-pandemic baseline was found. Among drug providers, from 15,835 to 21,233.
FDA warns against IVERMECTIN as a COVID treatment
The states with the largest increases in prescriptions were Idaho, New Mexico and Wyoming, each up 258%, 216%, and 204%, respectively, and the states with the largest increases in drug providers were New Mexico, South Dakota, and South Dakota. Alaska was. The report covers 172%, 118% and 117% respectively.
In addition, the specialty associated with the largest monthly increase in ivermectin prescriptions, such as anesthesiology, physical medicine and rehabilitation and pulmonary disease, does not typically treat conditions that fall under FDA-approved uses for the drug. Several approved uses for humans include conditions caused by parasitic worms as well as head lice and rosacea, and the report found a 14% drop in diagnoses of conditions under the drug’s approved uses. The authors write that 2020 is likely to decline due to lower health care access in general, but also suggest off-label use amid the pandemic.
Click here for full coronavirus coverage
“This indicates a related trend of departure from evidence-based care,” the report later added, “providers writing prescriptions against CDC, FDA, and other health agencies guidelines during a public health crisis are a systemic may indicate an issue that requires further research.”
The study had its limitations because it did not account for uninsured patients and therefore did not account for the total number of prescriptions and those prescriptions. The analysis also focused on provider-sourced ivermectin, not over-the-counter ivermectin for animals or vet-prescribed ivermectin.